The labeling for transmucosal buprenorphine products will now include a warning that the drug may cause serious dental problems such as tooth decay, cavities, oral infections, and tooth loss.Nurses and NPs should complete an oral history and assessment prior to patients beginning treatment. Patients should be informed of these potential adverse effects and encouraged to receive regular dental care.
Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.